Navigation Links
KemPharm Forms Physician Advisory Council Advocating "Intelligent Pain Therapeutic Development"
Date:10/23/2013

NORTH LIBERTY, Iowa, Oct. 23, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has formed a Physician Advisory Council and named renowned pain specialists, Jeffrey A. Gudin, MD, and Srinivas Nalamachu, MD, as its co-chairs.

In leading KemPharm's Physician Advisory Council, Drs. Gudin and Nalamachu will publicly advocate on behalf of medical professionals, patients and the broader pharmaceutical industry on the need for "intelligent pain therapeutic development" and the value of prodrugs for limiting the abuse-potential and constipation-related side effect of opioid-based medications.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "There continues to be significant interest across the pharmaceutical and pain management industries, as well as the general public, in developing better ways to treat and manage pain.  Teaming with Drs. Gudin and Nalamachu, we have launched our Physician Advisory Council to bring attention to the need for 'intelligent pain therapies' that not only effectively manage the symptoms of pain, but also benefit patients by addressing two critical issues with current opioid-based pain medications – abuse and constipation.  As public advocates, Drs. Gudin and Nalamachu will serve as resources for medical professionals, patients and the pharmaceutical industry with regard to the potential that prodrug-based pain therapeutics provide in limiting these side-effects."

Dr. Jeffrey Gudin is Co-Director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey, an affiliate of the Mount Sinai School of Medicine.  He is board certified in pain medicine and anesthesiology, and is board eligible in addiction medicine.  His clinical and research focus includes pain management, regional anesthesia, and preemptive analgesia, as well as increasing clinician awareness of pain assessment and management.

Dr. Gudin received his medical degree from Albany Medical College in Albany, NY.  Following a transitional internship in surgery, medicine, and anesthesiology at St. Barnabas Medical Center in Livingston, NJ, he completed a residency in anesthesiology at Yale University School of Medicine.  He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching.

Dr. Srinivas Nalamachu is President and Medical Director of the International Clinical Research Institute Inc. and Co-Director of the Pain Management Institute in Overland Park, KS.  In addition, Dr. Nalamachu is Clinical Assistant Professor in the Department of Rehabilitation Medicine at Kansas University Medical Center in Kansas City, KS and Clinical Assistant Professor in the Department of Internal Medicine at Kansas City University of Medicine and Biosciences in Kansas City, MO.  Certified by the American Board of Physical Medicine and Rehabilitation, Dr. Nalamachu is a member of the American Academy of Pain Management, American Pain Society, American Association of Electrodiagnostic Medicine and the International Association for Study of Pain.  In addition, he is on the editorial board of Pain Clinician.  His is the principal investigator in numerous studies involving breakthrough, chronic pain, low back pain, and neuropathic pain.  Dr. Nalamachu completed his medical education and mandatory internship from Kakatiya Medical College Teaching Hospitals, Warangal, India.

About KemPharm
KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com

www.kempharm.comFor KemPharm, Inc:

Media / Investor Contacts:Christal Mickle

Jason Rando / Claire Sojda 319-665-2575

Tiberend Strategic Advisors, Inc.info@kempharm.com

212.827.0020jrando@tiberend.comcsojda@tiberend.com


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
2. KemPharms KP201 to be Featured at PAINWeek 2013
3. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
4. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
5. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
6. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
7. Accuray to Showcase Clinical Utilization and Adoption of its Latest Advanced Product Platforms at ASTRO 2013
8. Indonesias Healthcare Reforms Create Opportunities But Also Present New Market Access Hurdles for the Multinational Pharmaceutical Industry
9. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
10. Safety Net Clinic and Hospital User Group Forms to Collaborate on 340B Drug Program Best Practices and Transparency Initiatives
11. Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):